{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T21:36:07Z","timestamp":1787002567471,"version":"build-2736575974"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T00:00:00Z","timestamp":1259625600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Nat Rev Drug Discov"],"published-print":{"date-parts":[[2009,12]]},"DOI":"10.1038\/nrd3051","type":"journal-article","created":{"date-parts":[[2009,12,1]],"date-time":"2009-12-01T10:50:11Z","timestamp":1259664611000},"page":"929-930","source":"Crossref","is-referenced-by-count":52,"title":["Telavancin"],"prefix":"10.1038","volume":"8","author":[{"given":"G. Ralph","family":"Corey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin E.","family":"Stryjewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wim","family":"Weyenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uma","family":"Yasothan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Kirkpatrick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"BFnrd3051_CR1","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.coph.2004.04.006","volume":"4","author":"F Van Bambeke","year":"2004","unstructured":"Van Bambeke, F. Glycopeptides in clinical development: pharmacological profile and clinical perspectives. Curr. Opin. Pharmacol. 4, 471\u2013478 (2004).","journal-title":"Curr. Opin. Pharmacol."},{"key":"BFnrd3051_CR2","doi-asserted-by":"publisher","first-page":"326","DOI":"10.7164\/antibiotics.57.326","volume":"57","author":"MR Leadbetter","year":"2004","unstructured":"Leadbetter, M. R. et al. Hydrophobic vancomycin derivatives with improved ADME properties: discovery of telavancin (TD-6424). J. Antibiot. 57, 326\u2013336 (2004).","journal-title":"J. Antibiot."},{"key":"BFnrd3051_CR3","doi-asserted-by":"publisher","first-page":"3043","DOI":"10.1128\/AAC.48.8.3043-3050.2004","volume":"48","author":"SS Hegde","year":"2004","unstructured":"Hegde, S. S. et al. Pharmacodynamics of telavancin (TD-6424), a novel bactericidal agent, against Gram-positive bacteria. Antimicrob. Agents Chemother. 48, 3043\u20133050 (2004).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd3051_CR4","unstructured":"Food and Drug Administration. FDA labelling information. FDA website [\n                    online\n                    \n                  ] (2009)."},{"key":"BFnrd3051_CR5","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1128\/AAC.49.3.1127-1134.2005","volume":"49","author":"DL Higgins","year":"2005","unstructured":"Higgins, D. L. et al. Telavancin, a multifunctional lipoglycopeptide, disrupts both cell wall synthesis and cell membrane integrity in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 49, 1127\u20131134 (2005).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd3051_CR6","doi-asserted-by":"publisher","first-page":"3375","DOI":"10.1128\/AAC.01710-08","volume":"53","author":"CS Lunde","year":"2009","unstructured":"Lunde, C. S. et al. Telavancin disrupts the functional integrity of the bacterial membrane through targeted interaction with the cell wall precursor lipid II. Antimicrob. Agents Chemother. 53, 3375\u20133383 (2009).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd3051_CR7","doi-asserted-by":"publisher","first-page":"2647","DOI":"10.1128\/AAC.01398-07","volume":"52","author":"KM Krause","year":"2008","unstructured":"Krause, K. M. et al. In vitro activity of telavancin against resistant Gram-positive bacteria. Antimicrob. Agents Chemother. 52, 2647\u20132652 (2008).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd3051_CR8","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1086\/587896","volume":"46","author":"ME Stryjewski","year":"2008","unstructured":"Stryjewski, M. E. et al. Telavancin versus vancomycin for the treatment of complicated skin and skin-structure infections caused by Gram-positive organisms. Clin. Infect. Dis. 46, 1683\u20131693 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrd3051_CR9","doi-asserted-by":"publisher","first-page":"309","DOI":"10.7326\/0003-4819-144-5-200603070-00005","volume":"144","author":"MD King","year":"2006","unstructured":"King, M. D. et al. Emergence of community-acquired methicillin-resistant Staphylococcus aureus USA 300 clone as the predominant cause of skin and soft-tissue infections. Ann. Intern. Med. 144, 309\u2013317 (2006).","journal-title":"Ann. Intern. Med."},{"key":"BFnrd3051_CR10","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1056\/NEJMoa055356","volume":"355","author":"GJ Moran","year":"2006","unstructured":"Moran, G. J. et al. Methicillin-resistant S. aureus infections among patients in the emergency department. N. Engl. J. Med. 355, 666\u2013674 (2006).","journal-title":"N. Engl. J. Med."},{"key":"BFnrd3051_CR11","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.1128\/JCM.01388-06","volume":"44","author":"G Wang","year":"2006","unstructured":"Wang, G. et al. Increased vancomycin MICs for Staphylococcus aureus clinical isolates from a university hospital during a 5-year period. J. Clin. Microbiol. 44, 3883\u20133886 (2006).","journal-title":"J. Clin. Microbiol."},{"key":"BFnrd3051_CR12","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1086\/527393","volume":"46","author":"FC Tenover","year":"2008","unstructured":"Tenover, F. C. Vancomycin-resistant Staphylococcus aureus: a perfect but geographically limited storm? Clin. Infect. Dis. 46, 675\u2013677 (2008).","journal-title":"Clin. Infect. Dis."},{"key":"BFnrd3051_CR13","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1128\/AAC.50.2.788-790.2006","volume":"50","author":"HK Sun","year":"2006","unstructured":"Sun, H. K. et al. Tissue penetration of telavancin after intravenous administration in healthy subjects. Antimicrob. Agents Chemother. 50, 788\u2013790 (2006).","journal-title":"Antimicrob. Agents Chemother."},{"key":"BFnrd3051_CR14","unstructured":"IMS MIDAS (IMS Health, 2009)."},{"key":"BFnrd3051_CR15","volume-title":"Specialty Pharmaceuticals","author":"I Sanderson","year":"2009","unstructured":"Sanderson, I. et al. Specialty Pharmaceuticals (Cowen and Company, 14 Sep 2009)."},{"key":"BFnrd3051_CR16","volume-title":"JP Morgan North America Equity Research Report","author":"M Urist","year":"2009","unstructured":"Urist, M. & Harr, S. JP Morgan North America Equity Research Report (JP Morgan & Chase, 23 Jul 2009)."}],"container-title":["Nature Reviews Drug Discovery"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/nrd3051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd3051","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/nrd3051.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,19]],"date-time":"2023-05-19T00:02:46Z","timestamp":1684454566000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/nrd3051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2009,12]]}},"alternative-id":["BFnrd3051"],"URL":"https:\/\/doi.org\/10.1038\/nrd3051","relation":{},"ISSN":["1474-1776","1474-1784"],"issn-type":[{"value":"1474-1776","type":"print"},{"value":"1474-1784","type":"electronic"}],"subject":[],"published":{"date-parts":[[2009,12]]}}}